GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InNexus Biotechnology Inc (GREY:IXSBF) » Definitions » Cyclically Adjusted PB Ratio

InNexus Biotechnology (InNexus Biotechnology) Cyclically Adjusted PB Ratio : (As of Jun. 22, 2024)


View and export this data going back to . Start your Free Trial

What is InNexus Biotechnology Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


InNexus Biotechnology Cyclically Adjusted PB Ratio Historical Data

The historical data trend for InNexus Biotechnology's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InNexus Biotechnology Cyclically Adjusted PB Ratio Chart

InNexus Biotechnology Annual Data
Trend Jun01 Jun02 Jun03 Jun04 Jun05 Jun06 Jun07 Jun08 Jun09 Jun10
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

InNexus Biotechnology Quarterly Data
Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of InNexus Biotechnology's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, InNexus Biotechnology's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InNexus Biotechnology's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InNexus Biotechnology's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where InNexus Biotechnology's Cyclically Adjusted PB Ratio falls into.



InNexus Biotechnology Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

InNexus Biotechnology's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2011 is calculated as:

For example, InNexus Biotechnology's adjusted Book Value per Share data for the three months ended in Mar. 2011 was:

Adj_Book=Book Value per Share/CPI of Mar. 2011 (Change)*Current CPI (Mar. 2011)
=-0.04/94.3376*94.3376
=-0.040

Current CPI (Mar. 2011) = 94.3376.

InNexus Biotechnology Quarterly Data

Book Value per Share CPI Adj_Book
200106 0.057 77.983 0.069
200109 0.049 77.904 0.059
200112 0.037 76.956 0.045
200203 0.110 78.141 0.133
200206 -0.099 78.931 -0.118
200209 0.060 79.721 0.071
200212 0.058 79.879 0.068
200303 0.053 81.459 0.061
200306 0.004 80.985 0.005
200309 0.014 81.459 0.016
200312 0.020 81.538 0.023
200403 0.016 82.091 0.018
200406 0.023 83.039 0.026
200409 0.012 82.960 0.014
200412 0.033 83.276 0.037
200503 0.023 83.987 0.026
200506 0.004 84.461 0.004
200509 0.014 85.647 0.015
200512 -0.010 85.015 -0.011
200603 -0.031 85.805 -0.034
200606 0.023 86.516 0.025
200609 0.123 86.279 0.134
200612 0.094 86.437 0.103
200703 0.035 87.780 0.038
200706 0.088 88.412 0.094
200709 0.078 88.412 0.083
200712 0.049 88.491 0.052
200803 0.035 88.965 0.037
200806 0.065 91.177 0.067
200809 0.039 91.414 0.040
200812 0.003 89.518 0.003
200903 -0.017 90.071 -0.018
200906 -0.025 90.940 -0.026
200909 -0.033 90.624 -0.034
200912 -0.027 90.703 -0.028
201003 -0.039 91.335 -0.040
201006 -0.041 91.809 -0.042
201009 -0.039 92.362 -0.040
201012 -0.036 92.836 -0.037
201103 -0.040 94.338 -0.040

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


InNexus Biotechnology  (GREY:IXSBF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


InNexus Biotechnology Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of InNexus Biotechnology's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


InNexus Biotechnology (InNexus Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
1055 West Georgia Street, 1500 Royal Centre, Vancouver, BC, CAN, V6E 4N7
InNexus Biotechnology Inc is engaged in commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications.

InNexus Biotechnology (InNexus Biotechnology) Headlines

No Headlines